Icatibant Aguettant

Icatibant, the active ingredient in Icatibant Aguettant, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous use. It treats hereditary angioedema (C1‑inhibitor deficiency) by providing rapid relief of acute swelling attacks in affected patients.

GNH USA supplies Icatibant Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema that works by blocking the bradykinin B2 receptor pathway.

- Hereditary angioedema type I: reduces severity and duration of acute swelling attacks. - Hereditary angioedema type II: provides rapid symptom relief during attacks. - Acute hereditary angioedema attacks: delivers fast onset of action to control life‑threatening edema.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe hypotension: marked drop in blood pressure. - Paradoxical angioedema: worsening swelling despite therapy. - Thrombocytopenia: reduced platelet count. - Severe injection‑site necrosis: rare tissue damage. - Pulmonary edema: rare fluid accumulation in lungs.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: no dosage adjustment required, but monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced edema. - Hypersensitivity: discontinue immediately if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence bradykinin pathways or edema risk.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may exacerbate angioedema. - Neprilysin inhibitors (e.g., sacubitril): increase bradykinin levels, heightening risk. - C1‑inhibitor concentrates: may reduce Icatibant efficacy when used concurrently.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: can worsen hereditary angioedema symptoms. - NSAIDs: may increase propensity for swelling. - Beta‑blockers: could mask early signs of anaphylaxis or hypotension.